Journal of Clinical Endocrinology & Metabolism, Vol 81, 44-48, Copyright © 1996 by Endocrine Society

ARTICLES

Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis

AG Johansson, E Lindh, WF Blum, G Kollerup, OH Sorensen and S Ljunghall
Department of Internal Medicine, University of Hospital, Uppsala, Sweden.

Injections with growth hormone (GH) or insulin-like growth factor I (IGF-I) have been proposed for anabolic therapy in osteoporosis. In a cross-over study, 12 men with idiopathic osteoporosis received daily subcutaneous injections of GH (2 IU/m2) or IGF-I (80 micrograms/kg) for 7 days with 12 weeks of wash-out. Serum levels of procollagen type I increased by 29% following treatment with GH (P < 0.001) and by 43% with IGF-I (P < 0.001 compared with pretreatment levels; P < 0.05 compared with GH injections), whereas both treatments rendered a 20% increase in osteocalcin concentrations (P < 0.001), indicating enhanced bone formation. There was also evidence of stimulated bone resorption, as the urinary levels of deoxypyridinoline increased by 44% following GH injections (P < 0.001) and by 29% following IGF-I (P < 0.001), and there were 28% higher serum concentrations of IGF-I after GH than after IGF-I injections. Although markers of bone metabolism increased under both treatments, comparison of the treatments suggests that IGF-I enhanced formation of collagen type I more than did GH. Furthermore, the stimulation of bone resorption was detected as soon as 4 days after the initiation of GH injections. Some of the differences might be dose- dependent, but could also indicate separate mechanisms at the cellular level.

This article has been cited by other articles:

				A. Giustina, G. Mazziotti, and E. Canalis Growth Hormone, Insulin-Like Growth Factors, and the Skeleton Endocr. Rev., August 1, 2008; 29(5): 535 - 559. [Abstract] [Full Text] [PDF]

				T. Ueland GH/IGF-I and bone resorption in vivo and in vitro Eur. J. Endocrinol., March 1, 2005; 152(3): 327 - 332. [Abstract] [Full Text] [PDF]

				B. Dawson-Hughes, S. S. Harris, H. Rasmussen, L. Song, and G. E. Dallal Effect of Dietary Protein Supplements on Calcium Excretion in Healthy Older Men and Women J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1169 - 1173. [Abstract] [Full Text] [PDF]

				P. Gillberg, H. Mallmin, M. Petren-Mallmin, S. Ljunghall, and A. G. Nilsson Two Years of Treatment with Recombinant Human Growth Hormone Increases Bone Mineral Density in Men with Idiopathic Osteoporosis J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4900 - 4906. [Abstract] [Full Text] [PDF]

				S. Boonen, C. Rosen, R. Bouillon, A. Sommer, M. McKay, D. Rosen, S. Adams, P. Broos, J. Lenaerts, J. Raus, et al. Musculoskeletal Effects of the Recombinant Human IGF-I/IGF Binding Protein-3 Complex in Osteoporotic Patients with Proximal Femoral Fracture: A Double-Blind, Placebo-Controlled Pilot Study J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1593 - 1599. [Abstract] [Full Text] [PDF]

				E. S. Kurland, F. Cosman, D. J. McMahon, C. J. Rosen, R. Lindsay, and J. P. Bilezikian Parathyroid Hormone as a Therapy for Idiopathic Osteoporosis in Men: Effects on Bone Mineral Density and Bone Markers J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3069 - 3076. [Abstract] [Full Text]

				M. Thearle, M. Horlick, J. P. Bilezikian, J. Levy, J. M. Gertner, L. S. Levine, M. Harbison, W. Berdon, and S. E. Oberfield Osteoporosis: An Unusual Presentation of Childhood Crohn's Disease J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2122 - 2126. [Abstract] [Full Text]

				M. E. Wilson Insulin-Like Growth Factor I (IGF-I) Replacement during Growth Hormone Receptor Antagonism Normalizes Serum IGF-Binding Protein-3 and Markers of Bone Formation in Ovariectomized Rhesus Monkeys J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1557 - 1562. [Abstract] [Full Text]

				B.-A. Bengtsson and G. Johannsson The Treatment of Growth Hormone Deficiency in Adults J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 933 - 937. [Full Text]

				A. Santhanagopal and S. J. Dixon Insulin-like growth factor I rapidly enhances acid efflux from osteoblastic cells Am J Physiol Endocrinol Metab, September 1, 1999; 277(3): E423 - E432. [Abstract] [Full Text] [PDF]

				C. J. Rosen, E. S. Kurland, D. Vereault, R. A. Adler, P. J. Rackoff, W. Y. Craig, S. Witte, J. Rogers, and J. P. Bilezikian Association Between Serum Insulin Growth Factor-I (IGF-I) and a Simple Sequence Repeat in IGF-I Gene: Implications for Genetic Studies of Bone Mineral Density J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2286 - 2290. [Abstract] [Full Text]

				C. Ohlsson, B.-A. Bengtsson, O. G. P. Isaksson, T. T. Andreassen, and M. C. Slootweg Growth Hormone and Bone Endocr. Rev., February 1, 1998; 19(1): 55 - 79. [Abstract] [Full Text]

				T. Bianda, Y. Glatz, R. Bouillon, E. R. Froesch, and C. Schmid Effects of Short-Term Insulin-Like Growth Factor-I (IGF-I) or Growth Hormone (GH) Treatment on Bone Metabolism and on Production of 1,25-Dihydroxycholecalciferol in GH-Deficient Adults J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 81 - 87. [Abstract] [Full Text]